Why This Headline Is Back
A Stanford finding described as a natural version of Ozempic has resurfaced across news feeds this month, and it is worth knowing why before deciding what to do about it.
The research itself is not new. It was published in Nature on March 5, 2025. What happened recently is that a science news aggregator recirculated the study, and the coverage spread again. The molecule has not advanced; no new results were released, and nothing about its availability has changed.
That distinction matters because a resurfaced headline creates a fresh wave of search traffic, and search traffic attracts sellers.
The finding is genuinely interesting. Researchers in the lab of Katrin Svensson, PhD, at Stanford Medicine used an algorithm called Peptide Predictor to screen roughly 2,600 previously uncharacterized peptide fragments, looking for ones that might regulate energy metabolism. They identified a 12-amino-acid peptide they named BRP, for BRINP2-related peptide, as Stanford described in coverage of the work. Senior research scientist Laetitia Coassolo, PhD, is the lead author.
Unlike semaglutide, which activates GLP-1 receptors in the gut, pancreas, brainstem and elsewhere, BRP appears to act primarily on POMC neurons in the hypothalamus, the brain region that governs hunger and energy use.
What the Research Actually Showed
The animal results are striking, and every one of them is an animal result.
In lean mice and minipigs, a single injection of BRP reduced food intake by up to 50 percent within an hour. In obese mice, daily injections over 14 days produced fat loss while lean muscle mass was preserved. The animals did not show the nausea, constipation or muscle loss that commonly accompany GLP-1 drugs.
That is the entire published human-relevance case: a mechanism that looks promising in two species, neither of which is human.
There is no human trial. As of mid-2026, no human study of BRP has been registered or reported. The FDA has not reviewed it. It is not sold in any pharmacy, clinic, or supplement aisle. Svensson has co-founded a company, Merrifield Therapeutics, to move the peptide toward clinical testing, and no investigational new drug filing or trial timeline has been publicly announced.
Two disclosures belong in any account of this work. Svensson and Coassolo are listed as inventors on patents tied to BRP peptides, and Svensson co-founded the company that intends to commercialize it. The underlying research was funded by the National Institutes of Health.
Where It Sits in the Drug Pipeline
The distance between this finding and a prescription is longer than most coverage conveys, and describing it plainly is the point of this article.
A molecule that suppresses feeding in mice has cleared the first of many gates. What follows is lead optimization, formulation work, and toxicology studies designed to establish whether the compound is safe enough to give a human at all. Only then can a company file an investigational new drug application. Phase 1 tests safety and dosing in a small number of volunteers. Phase 2 tests whether it does anything useful. Phase 3 tests it against a comparator in a large population, which is where most candidates that get that far still fail.
Weight-loss drug development has a particularly unforgiving history. Several appetite-targeting compounds that performed beautifully in animals were withdrawn or abandoned in humans because of psychiatric, cardiovascular, or hepatic effects that rodents never showed.
Even on an optimistic timeline with no setbacks, a compound at BRP's current stage is years from a pharmacy shelf, and the honest base rate is that most never arrive.
How to Recognize the Marketing That Follows
Sellers are already attached to this story, and the tells are consistent enough to list.
Vendor sites have published detailed BRP explainers that read like science journalism and end by recommending peptides the reader can buy today, typically compounded semaglutide, tirzepatide, or retatrutide. The BRP content is the traffic magnet. The sale is something else. One such site says the quiet part out loud, noting that anyone selling BRP online is either lying or selling an unverified compound.
Watch for the phrase "research use only" or "not for human consumption." That labeling exists so a seller can ship a substance without a prescription while disclaiming responsibility for what happens next. It is not a technicality. It signals a product made outside pharmaceutical manufacturing standards.
Treat the word "natural" carefully here too. BRP occurs naturally inside the body. It cannot be eaten, brewed, extracted from a plant, or bought as a supplement, and a capsule claiming to boost it is not the molecule in the study.
Injectable products from unverified sources carry a specific risk beyond whether the contents are correct. Sterile preparation is a licensed manufacturing discipline, and an injection bypasses every barrier the body uses to filter what enters it. Contamination goes directly into tissue.
The regulatory environment around compounded peptides is unsettled. An FDA advisory committee voted on several compounded peptides in July 2026 after agency scientists recommended against them, an unresolved process that MedicalDaily has covered.
What to Do Instead
The useful response to an interesting preclinical finding is to follow it, not to buy something adjacent to it.
If you are struggling with side effects on a GLP-1 drug, that is a conversation with your prescriber about dose adjustment, titration pace, formulation, or a different agent. Those are real options available now with real safety data behind them.
If cost is the barrier, ask about manufacturer patient assistance programs, direct-purchase pricing, and whether a formulary exception applies to your plan. Those routes are unglamorous, and they are legitimate.
If you want to know when BRP becomes real, the signal to watch is the first registered human trial from Merrifield Therapeutics. Until a Phase 1 study appears in a clinical trials registry, there is nothing to evaluate.
Nothing about your care changes today because of this headline. MedicalDaily will report the first registered human trial, any investigational new drug filing, and FDA enforcement actions against sellers marketing unapproved peptides.
Frequently Asked Questions
Can I buy BRP? No. It is not approved, not available in any pharmacy or clinic, and has never been tested in humans. Anything sold under that name online is unverified.
What did the study actually show? In mice and minipigs, a single injection cut food intake by up to 50 percent within an hour, and daily injections in obese mice produced fat loss with preserved muscle, without nausea or constipation.
Why is it in the news again now? A science news outlet recirculated the March 2025 Nature paper this month. No new results were released.
How is it different from Ozempic? Semaglutide activates GLP-1 receptors across multiple tissues. BRP appears to act mainly on POMC neurons in the hypothalamus.
When could it be available? Unknown. No human trial has been registered. Even without setbacks, a compound at this stage is years from approval, and most never reach it.
Is it safe? Nobody knows. Safety in humans cannot be inferred from mice and minipigs.
What should I do if a site offers to sell it? Do not buy it. Labeling such as "research use only" indicates a product made outside pharmaceutical manufacturing standards, and injectables from unverified sources carry contamination risk.
